Founders join cutting-edge therapeutics company as part of senior management team.
Closed Loop Medicine (CLM), the Cambridge-based health tech startup that helps doctors and healthcare providers to deliver personalised treatment regimens to patients, announces its top executive team which includes some of the UK’s leading experts in life sciences, healthcare technology and digital health.
Closed Loop Medicine (CLM) is a new breed of therapeutics company focused on care pathways, outcomes and the provision of dynamic personalised regimens. The company combines proven drugs with digital therapeutics enabling the digitisation and data capture of an entire care continuum. Digital therapeutics deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes.
To create such a multi-disciplined approach to medical care, CLM has brought together some of the UK’s most experienced healthcare professionals who are at the top of their specific areas of expertise and who together had the vision to create a totally new approach to patient care.
The new CLM management team includes:
Dr Hakim Yadi OBE, a co-founder of CLM, is the new chief executive officer. He was the founding CEO of the Northern Health Science Alliance Ltd (NHSA), which was at the forefront of establishing multi-partner collaborations between healthcare systems and leading industry from med-tech to pharma, biotech and digital health companies. Dr Yadi holds a PhD in molecular biology from the University of Cambridge, and previously worked for PA Consulting and as an adviser to the UK Government’s life sciences team. Dr Yadi was awarded an OBE for services to healthcare technology and the economy in the 2017 New Years Honours List.
Dr Paul Goldsmith, a co-founder, is to be President and Chief Innovation Officer. He is a consultant physician with a triple first from Cambridge and a clinical scholarship from Oxford. His PhD utilised the simplicity of developmental biology to understand complex human disease. Dr Goldsmith went on to co-found and help build two drug discovery and two digital health companies. He also has extensive NHS systems and strategic experience, including Clinical Networks, Vanguard and Clinical Senate roles.
Dr David Cox, a co-founder, is to be Chief Digital Officer. He has built a career operating on the boundaries between healthcare, technology and business. Dr Cox practiced medicine for several years after studying at the University of Cambridge before pursuing a management career, gaining experience first at McKinsey & Co. For several years now he has focused on the growing promise of digital health, starting his own health app company, and then moving on to help grow other startups in senior management positions. He is a mentor on the NHS Clinical Entrepreneur Training programme.
Dr Felicity Sartain, a co-founder, is to be Chief Operations Officer. Dr Sartain has experience of managing and running projects in the private and public sectors and has hands-on experience in commercial R&D. Prior to joining CLM, Felicity set up and ran her own consultancy business. She holds a PhD in biotechnology from the University of Cambridge and an MChem in Chemistry with Life Sciences and Pharmaceuticals from the University of York. She is an advisor to the European Healthtech Translation Advisory Board (HealthtechTAB).
Chris Poole is Chief Financial Officer. He is a qualified Chartered Accountant and has over 20 years experience in top finance roles within small start-ups through to a FTSE 250 listed company.
Dr Andy Richards CBE is the chairman. He one of the foremost life sciences entrepreneurs in the Country and is also a Director of Ieso Digital Health, and Chairman of Arecor, Congenica, Abcodia, and the Babraham Research Campus.
Dr Richards said: ‘Collectively the CLM team each brings independent domain expertise needed to develop a fully integrated, evidenced backed product. Hakim’s expertise of health systems and strategic collaboration, Paul’s clinical insight and expertise in drug development, David’s know-how of behaviour change and the future of medicine combined with Felicity’s ability to bring together and manage complex interdependent programmes and Chris’ financial acumen means we have a high functioning team embedded with the discipline to make things happen.
“We have created a dream team of health technology and life science expertise with the right vision and ambition to succeed in the new world of convergent technology. Its experience and professionalism will enable it to both progress clinical development of its pipeline and form strong partnerships with healthcare providers and pharmaceutical companies’’.
About Closed Loop Medicine
Closed Loop Medicine is a Cambridge-based therapeutics company focused on care pathways, outcomes and the provision of dynamic personalised regimens. CLM has a development pipeline that integrates Drug + Digital+ Device for the treatment of some of the biggest challenges facing global health systems. For now, CLM is working on treating sleep disorders and hypertension but in the future will be working on other health problems.
By focusing on individual care pathways, CLM can augment proven drugs with digital therapeutics enabling the digitisation and data capture of an entire care continuum for dynamic personalised regimens. Digital therapeutics deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease.
The founders of CLM have a track record of working together and between them have launched many highly successful commercial enterprises including drugs, digital health, diagnostics and devices. The team has full experience of technology development through to market access, reimbursement and uptake.
CLM was founded in 2017. Its HQ is in London, UK.